Revance Therapeutics, Inc. (RVNC) Receives Average Rating of “Buy” from Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given an average rating of “Buy” by the eight analysts that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $37.00.

A number of research analysts recently commented on the company. BidaskClub cut Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Mizuho assumed coverage on Revance Therapeutics in a report on Thursday, November 16th. They issued a “buy” rating and a $37.00 price objective on the stock. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Piper Jaffray Companies set a $28.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, November 16th.

In other news, Director Mark J. Foley purchased 20,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were bought at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the completion of the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at $161,760. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Lauren P. Silvernail sold 10,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $26.83, for a total value of $268,300.00. Following the transaction, the chief financial officer now owns 59,006 shares in the company, valued at $1,583,130.98. The disclosure for this sale can be found here. Insiders have sold 36,426 shares of company stock worth $945,690 over the last 90 days. 18.86% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. lifted its stake in Revance Therapeutics by 1.0% during the second quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock worth $604,000 after purchasing an additional 225 shares in the last quarter. Legal & General Group Plc lifted its stake in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 438 shares in the last quarter. American International Group Inc. lifted its stake in Revance Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 834 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Revance Therapeutics by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 1,275 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Revance Therapeutics by 5.9% during the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 1,524 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Shares of Revance Therapeutics (RVNC) opened at $24.55 on Wednesday. Revance Therapeutics has a 52-week low of $15.85 and a 52-week high of $28.75.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s revenue was up .0% on a year-over-year basis. sell-side analysts forecast that Revance Therapeutics will post -3.73 EPS for the current fiscal year.

WARNING: “Revance Therapeutics, Inc. (RVNC) Receives Average Rating of “Buy” from Analysts” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/22/revance-therapeutics-inc-rvnc-receives-average-rating-of-buy-from-analysts.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply